Advancing Pathways for the Development of Innovative Therapies for Children with Inflammatory Bowel Disease (IBD)

Virtual Public Webinar Series:
November 9, 10, and 17 from 9 a.m.-13:00 ET, (3 p.m. CET)
Fourth series event in January 2022

Hosted by I-ACT for Children, the forum goals are:

- Develop solutions to move our industry forward and advance pathways for regulatory approval and labeling of IBD therapies for use in children
- Unite all stakeholders to gain perspective and solutions, including patients and families, clinicians, sponsors and regulators
- Identify knowledge gaps that impact the development process and recommend actionable items to address these gaps
- Construct a road map that can be used by investigators, funding agencies and sponsors to support further advancement of pediatric IBD therapeutics development

Inflammatory bowel disease (IBD), once considered rare in children, is now common enough that most pediatricians and clinicians will encounter children with some type of IBD. Addressing the needs of children with IBD related to drug development of new therapies has emerged as a challenging issue. The goal of this Forum is to identify how these challenges can be met.
Our Approach

The Pediatric Research Innovation Forum involves pre-meeting working group sessions from July through October 2021, followed by three webinars in November 2021 and one in January 2022. These webinars will solicit broader public feedback. The working groups’ feedback from the meetings will be summarized in a postmeeting summary of recommendations.

Each working group has two assigned co-chairs — one from the United States and one from Europe. I-ACT for Children is facilitating the working group meetings and the webinars for the public forum.

The four topics are:

1. Perspectives: Patient, Family and Healthcare Providers
2. Data Extrapolation
3. Real-World Data (RWD)/Real-World Evidence (RWE); Biomarkers & Endpoints
4. Clinical Trial Designs

Join us for any of these public webinars or the entire series.

Register Today

Pediatric Research INNOVATION FORUM

This Forum has been supported in part by a grant from the US Food and Drug Administration (award #5Y18FD006297), in addition to educational grants received from Eli Lilly and Company, Janssen Research & Development LLC, and the Pharmaceutical Research and Manufacturers of America.

In Collaboration: